一项评估对氯-2-[18F]氟乙基依托咪酯在健康志愿者和原发性醛固酮增多症患者中安全性与肾上腺摄取I/IIa期临床试验
该I/IIa期单中心开放标签微剂量研究纳入6例原发性醛固酮增多症患者(3例单侧、3例双侧)和5名健康志愿者,评估对氯-2-[18F]氟乙基依托咪酯([18F]CETO)的安全性及肾上腺摄取。结果显示无严重不良事件,所有参与者肾上腺功能正常,[18F]CETO对肾上腺高选择性,地塞米松预处理可抑制正常肾上腺摄取并增强醛固酮瘤显影。
要点
- 11名参与者(6例患者、5名健康志愿者)中无严重不良事件或反应,肾上腺功能均正常。
- [18F]CETO对肾上腺高选择性,其他组织摄取低。
- 地塞米松预处理可抑制正常肾上腺对[18F]CETO的摄取,增强醛固酮瘤显影。
核心结论
- [18F]CETO是安全的肾上腺PET显像放射性药物,本研究中未见不良反应或肾上腺功能损害。
- [18F]CETO对肾上腺组织尤其醛固酮瘤显示选择性高亲和力。
- 地塞米松预处理抑制正常腺体摄取,增强醛固酮瘤与正常肾上腺组织的区分。
- [18F]CETO有望成为评估原发性醛固酮增多症的影像工具。
研究设计与样本
- I/IIa期、单中心、开放标签、微剂量研究。
- 主要目的为评估最多2次[18F]CETO给药在6例原发性醛固酮增多症患者(3例单侧、3例双侧)和5名健康志愿者中的安全性。
- 安全性评估包括首次[18F]CETO给药后肾上腺功能评估。
- 通过90分钟动态PET采集评估[18F]CETO的生物分布。
- 在原发性醛固酮增多症患者中还评估了口服地塞米松预处理对正常肾上腺组织和醛固酮瘤摄取[18F]CETO的影响。
主要发现
- 共招募11名参与者,包括6例患者和5名健康志愿者。
- 无受试者发生严重不良事件或反应,所有参与者[18F]CETO给药后肾上腺功能正常。
- [18F]CETO对肾上腺高选择性,其他组织摄取低。
- 地塞米松预处理后醛固酮瘤显影增强,正常肾上腺组织对[18F]CETO的摄取被抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary aldosteronism (PA) is a common, potentially reversible, cause of hypertension. Distinguishing unilateral from bilateral PA is critical when deciding who should be offered surgery (unilateral adrenalectomy). Recent studies have shown that PET/CT with [11C]metomidate can accurately identify unilateral PA, with localization of the causative aldosterone-producing adenoma (APA). However, the availability of [11C]metomidate is limited to centers with an on-site cyclotron. Here, we report an early-phase human study with the 18F-labeled analog, para-chloro-2-[18F]fluoroethyletomidate ([18F]CETO). Methods: We conducted a phase I/IIa, single-center, open-label, microdosing study. The primary objective was to evaluate the safety of up to 2 administrations of [18F]CETO in 6 patients with PA (3 unilateral disease, 3 bilateral disease) and 5 healthy volunteers. Safety evaluation included assessment of adrenal function after the first [18F]CETO administration. The biodistribution of [18F]CETO was assessed in a 90-min dynamic PET acquisition. In patients with PA, the effect of pretreatment with oral dexamethasone on [18F]CETO uptake by normal adrenal tissue and APAs was also assessed. Results: Eleven participants were recruited to the trial, including 6 patients and 5 healthy volunteers. No subjects experienced serious adverse events or reactions, and all participants had normal adrenal function after [18F]CETO administration. [18F]CETO demonstrated high selectivity for the adrenal glands with low uptake in other tissues. Visualization of APAs was enhanced after dexamethasone pretreatment, which suppressed [18F]CETO uptake by normal adrenal tissue. Conclusion: [18F]CETO is a safe radiopharmaceutical for PET imaging of the adrenal glands, with no observed adverse reactions or impairment of adrenal function in this study. [18F]CETO demonstrates selective high affinity for adrenal tissue, particularly APAs. Distinction between APAs and normal adrenal tissue is enhanced by dexamethasone pretreatment to suppress [18F]CETO uptake by normal glands. This positions [18F]CETO as a promising imaging tool for evaluation in the context of PA.
引用
- Gillett D, Senanayake R, MacFarlane J, et al. A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism. J Nucl Med. 2025. PMID: 39884776. doi:10.2967/jnumed.124.268425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。